InVitae Countersues Myriad in Northern California District Court | GenomeWeb

NEW YORK (GenomeWeb News) – Invitae has countersued Myriad Genetics in the US District Court for the Northern District of California seeking declaratory judgment that certain claims held by Myriad on BRCA1/2 and MUTYH genes are invalid and are not infringed by Invitae.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.